A PRECEDEâ€“PROCEED MODEL ON THE DETERMINANTS OF ADHERENCETO HIV TREATMENT: A PATH ANALYSIS EVIDENCE FROM INDONESIA
Objective: Adherence is increasingly recognized as an important determinant of successful HIV treatment (also called antiretroviral therapy [ART]). Poor adherence may cause ART failure and increase the risk of drug resistance. No prior studies have explained the reasons for poor adherence to ART among HIV-infected patients in Indonesia. This study aimed to investigate the determinants of adherence to ART among HIV-infected patients using precedeâ€“proceed model and path analysis.
Methods: This was an analytic observational study with a cross-sectional design. The study was carried out at Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia, from January to March 2018. A total of 284 HIV-infected patients visiting Dr. Moewardi Hospital for ART was selected for this study by simple random sampling. The dependent variable was adherence to ART. The independent variables included adverse effect, patient knowledge, income, depression, trust in provider, ART supply by the government, family support, stigma, discrimination, distance, and travel expenditure. The data were collected by pre-tested questionnaire and analyzed by path analysis.
Results: Adherence to ART was directly and positively affected by government supply of ART (b=2.10; 95% confidence interval (CI)=0.85â€“3.36; p<0.001), patient knowledge (b=1.70; 95% CI= 0.43â€“2.95; p=0.008), and trust in provider (b=2.14; 95% CI=âˆ’0.58â€“4.87; p = 0.123). Adherence was directly but negatively affected by adverse effect (b=âˆ’4.17; 95% CI=âˆ’6.87â€“âˆ’1.47 ; p=0.879), depression (b=âˆ’2.38; 95% CI=âˆ’4.15â€“âˆ’0.62 ; p=0.002), stigma (b=âˆ’4.10; 95% CI=âˆ’6.49â€“âˆ’1.71; p=0.008), and travel expenditure (b=âˆ’1.52; 95% CI=âˆ’2.68 to âˆ’0.36; p<0.001).
Conclusion: Adherence is indirectly and positively affected by patient satisfaction, income, family support, but indirectly and negatively affected by discrimination and distance. This study concludes that government supply of ART, patient knowledge, and trust in provider, positively affect adherence to ART. Adverse effect, depression, stigma, and travel expenditure negatively affect adherence.
2. Giordano TP, Suarez-Almazor ME, Grimes RM. The population effectiveness of highly active antiretroviral therapy: Are good drugs good enough? Curr HIV/AIDS Rep 2005;2:177-83.
3. Greenberg AE, Hader SL, Masur H, Young AT, Skillicorn J, Dieffenbach CW. Fighting HIV/AIDS in Washington, D.C. Health Aff 2009;28:1677-87.
4. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011;52:793 800.
5. Rabba AK, Aljiris WS, Ahmed NJ, Alkharfy KM. Medication adherence in Type 2 diabetic patients: A study in Saudi Arabia. Int J Pharm Pharm Sci 2017;9:247-50.
6. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30 Suppl 2:S96 116.
7. Masikini P, Mpondo BC. HIV drug resistance mutations following poor adherence in HIV-infected patient: A case report. Clin Case Rep 2015;3:353-6.
8. Shaji J, Shaikh M. Drug-resistant tuberculosis: Recent approach in polymer based nanomedicine. Int J Pharm Pharm Sci 2016;8:1-6.
9. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004;53:696-9.
10. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives using HIV surveillance dataâ€”United States and 6 dependent areas, 2014. HIV Surveill Suppl Rep 2016;21. Available from: https://www.cdc.gov/hiv/pdf/ library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf.
11. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia- Cardenas V. Economic impact of medication non-adherence by disease groups: A systematic review. BMJ Open 2018;8:e016982.
12. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infect Dis 2012;12:296.
13. Green LW, Kreuter MW. CDCâ€™s planned approach to community health as an application of PRECEDE and an inspiration for PROCEED. J Health Educ 1992;23:140-7.
14. Crosby R, Noar SM. What is a planning model? An introduction to PRECEDE-PROCEED. J Public Health Dent 2011;71 Suppl 1:S7-15.
15. Harm Research Institute. MINI. Harm Research Institute; 2018. Available from: http://www.harmresearch.org/index.php/mini-international-neuropsychiatric-interview-mini/#About%20the%20 MINI. [Last accessed on 2018 Jun].
16. Crow JF. Sewall Wright. 1889â€”1988. Washington DC: National Academy of Science; 1994.
17. StataCorp LLC. Structural Equation Modeling (SEM). College Station, TX, USA: StataCorp LLC.; 2018.
18. Available from: https://www.stata.com/features/structural-equation-modeling/. [Last accessed on 2018 Jun].
19. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis. AIDS Care 2013;25:400-14.
20. Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7.
21. Joglekar N, Paranjape R, Jain R, Rahane G, Potdar R, Reddy KS, et al. Barriers to ART adherence and follow ups among patients attending ART centres in Maharashtra, India. Indian J Med Res 2011;134:954-9.
22. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M, et al. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in northern tanzania. AIDS Patient Care STDS 2014;28:98-105.
23. Prasitsuebsai W, Sethaputra C, Lumbiganon P, Hansudewechakul R, Chokephaibulkit K, Truong KH, et al. Adherence to antiretroviral therapy, stigma and behavioral risk factors in HIV-infected adolescents in asia. AIDS Care 2018;30:727-33.
24. Kingori C, Reece M, Obeng S, Murray M, Shacham E, Dodge B, et al. Impact of internalized stigma on HIV prevention behaviors among HIV-infected individuals seeking HIV care in Kenya. AIDS Patient Care and STDs 2012;26:761-8.
25. White W, Grant JS, Pryor ER, Keltner NL, Vance DE, Raper JL. Do social support, stigma, and social problem-solving skills predict depressive symptoms in people living with HIV? A mediation analysis. Res Theory Nurs Pract 2014;26:182-204. Sweeney SM, Vanable PA. The association of HIV-related stigma to HIV medication adherence: A systematic review and synthesis of the literature. AIDS Behav 2015;20:29-50.
26. Cook KS, Kramer RM, Thom DH, Stepanikova I, Mollborn SB, Cooper RM, et al. Trust and distrust in patientâ€“physician relationships: Perceived determinants of high- and low-trust relationships in managed-care settings. Trust and Distrust in Organizations: Dilemmas and Approaches, 2004. New York: Russell Sage Foundation. 2014. p. 65-98.
27. Abel WM, Efird JT. The association between trust in health care providers and medication adherence among black women with hypertension. Front Public Health 2013;1:66.
28. Dang BN, Westbrook RA, Black WC, Rodriguez-Barradas MC, Giordano TP. Examining the link between patient satisfaction and adherence to HIV care: A structural equation model. PLoS One 2013;8:e54729.
29. Shigdel R, Klouman E, Bhandari A, Ahmed LA. Factors associated with adherence to antiretroviral therapy in HIV-infected patients in Kathmandu District, Nepal. HIV AIDS (Auckl) 2014;6:109-16.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.